SG Americas Securities LLC raised its stake in shares of Novavax, Inc. (NASDAQ:NVAX – Free Report) by 0.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,158,967 shares of the biopharmaceutical company’s stock after purchasing an additional 4,691 shares during the quarter. SG Americas Securities LLC owned 0.72% of Novavax worth $9,318,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently modified their holdings of NVAX. Amalgamated Bank boosted its stake in Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,036 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in shares of Novavax by 3.0% in the 2nd quarter. Ensign Peak Advisors Inc now owns 44,900 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 1,300 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,598 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Novavax by 12.0% in the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 2,072 shares during the last quarter. Finally, Creative Planning lifted its holdings in Novavax by 12.5% during the 2nd quarter. Creative Planning now owns 24,143 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 2,692 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have weighed in on NVAX shares. Jefferies Financial Group decreased their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. B. Riley restated a “buy” rating and set a $26.00 price target (up from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Novavax presently has a consensus rating of “Hold” and a consensus target price of $17.83.
Novavax Price Performance
NVAX stock opened at $9.55 on Friday. The stock has a market capitalization of $1.53 billion, a PE ratio of -4.23 and a beta of 2.07. The company has a 50 day moving average price of $8.65 and a 200 day moving average price of $10.95. Novavax, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $23.86.
Novavax (NASDAQ:NVAX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million for the quarter, compared to analyst estimates of $65.80 million. The company’s revenue was down 54.8% compared to the same quarter last year. During the same period last year, the company earned ($1.26) EPS. As a group, equities analysts expect that Novavax, Inc. will post -1.31 earnings per share for the current fiscal year.
Insider Transactions at Novavax
In other Novavax news, Director James F. Young sold 4,600 shares of Novavax stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the sale, the director now owns 57,160 shares of the company’s stock, valued at approximately $484,716.80. The trade was a 7.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rachel K. King sold 4,150 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 in the last quarter. 1.00% of the stock is owned by company insiders.
Novavax Profile
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Recommended Stories
- Five stocks we like better than Novavax
- What is the Shanghai Stock Exchange Composite Index?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Pros And Cons Of Monthly Dividend Stocks
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What is Put Option Volume?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.